Kirsten E Smith1, Jeffery M Rogers1, Justin C Strickland2, David H Epstein1. 1. National Institute on Drug Abuse Intramural Research Program, Translational Addiction Medicine Branch, Baltimore, MD, USA. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
Background: Originally believed to be an atypical antidepressant acting at serotonin transporters, tianeptine is now known to also be an atypical agonist at mu-opioid receptors. Its nonmedical use may be increasing amidst the broader context of novel drug and supplement use. Objectives: To analyze social-media text from current, former, and prospective tianeptine users for better understanding of their conceptualizations of tianeptine, motives for and patterns of use, and reported benefits and harms. Methods: Reddit posts were obtained and thematically coded; additional quantitative analyses were conducted. Results: A total of 210 posts mentioning tianeptine were made between 2012 and 2020. Eighteen thematic categories were identified, 10 of which were consistent with expected themes. Two independent raters coded all text, generating 1,382 unique codes, of which 1,090 were concordant (78.9% interrater agreement). Tianeptine use was frequently associated with use of other drugs, particularly kratom, phenibut, and racetams. People conceptualized and variously used tianeptine as an opioid, antidepressant, and "nootropic" (cognitive enhancer). Between 2014 and 2020, mentions of positive effects decreased, while mentions of adverse effects and withdrawal increased. Motivations for use included substitution or withdrawal mitigation for other drugs (especially opioids) and for kratom itself; self-treatment for psychiatric symptoms; and improvement of quality of life, mood, or performance. Descriptions of tolerance, withdrawal, and addiction were evident. Intravenous use was rare and strongly discouraged, with detrimental effects described. Conclusion: Tianeptine is recognized as an opioid (though not only an opioid) in online communities. Posts describe benefits, acute risks, and patterns of co-use that warrant greater clinical attention.
Background: Originally believed to be an atypical antidepressant acting at serotonin transporters, tianeptine is now known to also be an atypical agonist at mu-opioid receptors. Its nonmedical use may be increasing amidst the broader context of novel drug and supplement use. Objectives: To analyze social-media text from current, former, and prospective tianeptine users for better understanding of their conceptualizations of tianeptine, motives for and patterns of use, and reported benefits and harms. Methods: Reddit posts were obtained and thematically coded; additional quantitative analyses were conducted. Results: A total of 210 posts mentioning tianeptine were made between 2012 and 2020. Eighteen thematic categories were identified, 10 of which were consistent with expected themes. Two independent raters coded all text, generating 1,382 unique codes, of which 1,090 were concordant (78.9% interrater agreement). Tianeptine use was frequently associated with use of other drugs, particularly kratom, phenibut, and racetams. People conceptualized and variously used tianeptine as an opioid, antidepressant, and "nootropic" (cognitive enhancer). Between 2014 and 2020, mentions of positive effects decreased, while mentions of adverse effects and withdrawal increased. Motivations for use included substitution or withdrawal mitigation for other drugs (especially opioids) and for kratom itself; self-treatment for psychiatric symptoms; and improvement of quality of life, mood, or performance. Descriptions of tolerance, withdrawal, and addiction were evident. Intravenous use was rare and strongly discouraged, with detrimental effects described. Conclusion: Tianeptine is recognized as an opioid (though not only an opioid) in online communities. Posts describe benefits, acute risks, and patterns of co-use that warrant greater clinical attention.
Authors: Anselm Wong; Mark Little; David Caldicott; Chris Easton; Daniel Andres; Shaun L Greene Journal: Clin Toxicol (Phila) Date: 2015-06-24 Impact factor: 4.467
Authors: Albert Garcia-Romeu; David J Cox; Kirsten E Smith; Kelly E Dunn; Roland R Griffiths Journal: Drug Alcohol Depend Date: 2020-02-03 Impact factor: 4.492
Authors: Michael A Downes; Ingrid L Berling; Ahmed Mostafa; Jeffrey Grice; Michael S Roberts; Geoffrey K Isbister Journal: Clin Toxicol (Phila) Date: 2015-06-26 Impact factor: 4.467
Authors: Benjamin Adam Samuels; Katherine M Nautiyal; Andrew C Kruegel; Marjorie R Levinstein; Valerie M Magalong; Madalee M Gassaway; Steven G Grinnell; Jaena Han; Michael A Ansonoff; John E Pintar; Jonathan A Javitch; Dalibor Sames; René Hen Journal: Neuropsychopharmacology Date: 2017-03-17 Impact factor: 7.853
Authors: Rhiannon Bath; Tanner Bucholz; Amy F Buros; Darshan Singh; Kirsten E Smith; Charles A Veltri; Oliver Grundmann Journal: J Addict Med Date: 2020 May/Jun Impact factor: 4.647
Authors: Marc T Swogger; Kirsten E Smith; Albert Garcia-Romeu; Oliver Grundmann; Charles A Veltri; Jack E Henningfield; Lorna Y Busch Journal: Front Pharmacol Date: 2022-03-02 Impact factor: 5.810
Authors: Kirsten E Smith; Jeffrey M Rogers; Kelly E Dunn; Oliver Grundmann; Christopher R McCurdy; Destiny Schriefer; David H Epstein Journal: Front Pharmacol Date: 2022-03-01 Impact factor: 5.810